Hypothesis

Rapamycin‑mediated mTORC1 inhibition extends lifespan by augmenting the cell’s capacity to selectively remove damaged mitochondrial proteins via mitophagy, thereby allowing cells to function despite persistent lipid peroxidation adducts. This mechanism represents a tolerance strategy rather than a repair strategy: rapamycin does not lower HNE/MDA adduct levels but increases the flux of damaged mitochondria to lysosomes for degradation.

Mechanistic Rationale

1. mTORC1 suppression activates the transcription factor ATF4, which upregulates genes involved in lysosomal biogenesis and the mitophagy receptor BNIP3/NIX (see ATF4‑dependent stress response).
2. Enhanced BNIP3/NIX promotes recruitment of the autophagic machinery to depolarized or damaged mitochondria, facilitating their engulfment by autophagosomes.
3. Because rapamycin does not alter the rate of HNE/MDA adduct formation (mitochondrial adduct accumulation), the net effect is a higher turnover of damaged organelles, preserving overall respiratory capacity.
4. This contrasts with direct antioxidant approaches (e.g., mitochondrial‑targeted catalase) that lower adduct formation (true damage prevention).

Testable Predictions

• Rapamycin treatment will increase mitophagy flux (measured by mt‑Keima or LC3‑colocalization with mitochondria) in aged tissues without changing steady‑state levels of HNE/MDA‑protein adducts.
• Genetic or pharmacological inhibition of mitophagy (e.g., BNIP3/NIX knockout or chloroquine treatment) will abolish the lifespan‑extending effect of rapamycin while leaving adduct levels unchanged.
• Overexpression of BNIP3/NIX in wild‑type animals will mimic rapamycin’s lifespan extension, whereas ATF4 knockdown will block both mitophagy induction and longevity benefits.
• Combined rapamycin and mitochondrial‑targeted catalase will not produce additive lifespan extension, indicating convergence on a common tolerance pathway.

Experimental Approach

1. Measure mitophagy flux in liver, muscle, and brain of young and old mice treated with rapamycin or vehicle using mt‑Keima reporter assay; quantify adduct levels via dot‑blot for HNE/MDA.
2. Interfere with mitophagy: generate BNIP3/NIX double‑conditional knockout mice; administer rapamycin and monitor survival, adduct burden, and respiratory function.
3. Rescue experiments: deliver AAV‑BNIP3/NIX to aged wild‑type mice; assess lifespan and compare to rapamycin‑treated cohorts.
4. Epistasis test: combine rapamycin with mitochondrial‑targeted catalase (MCAT) transgenic mice; evaluate whether lifespan extension exceeds that of either intervention alone.

Falsifiability

If rapamycin fails to raise mitophagy flux, or if blocking mitophagy does not diminish its longevity effect despite unchanged adduct levels, the hypothesis would be refuted. Conversely, a consistent increase in mitophagy flux coupled with dependency on this pathway for lifespan support would substantiate the model that rapamycin impersonates a harsher environment by enhancing cellular tolerance through selective organelle turnover, not by removing the underlying molecular damage.